Atara Biotherapeutics Inc (ATRA)
NASDAQ:ATRA
Want to see ATRA full AI Analyst Report?
Top Page
Atara Biotherapeutics
(NASDAQ:ATRA)
Select Model
Select Model
Rating:50Neutral
Price Target:
$10.50
▼(-33.50% Downside)
Action:Reiterated
Date:05/14/26
Overall score is held down primarily by weak financial performance (sharp revenue contraction, ongoing losses, negative equity, and persistent cash burn). Technicals are supportive due to strong momentum and price above major moving averages, but overbought RSI limits confidence. Corporate events are mixed, with regulatory pathway improvement offset by delisting risk, while valuation is constrained by loss-making fundamentals and no dividend support.
Positive Factors
High gross margins
Reported gross margin near 96% implies strong unit economics for Atara’s biologics if commercialized. Durable high margins support long-term profitability per therapy sold and improve the potential return on successful R&D investments, partially offsetting development-stage cost intensity.
Negative Factors
Sharp revenue contraction
An ~81% TTM revenue decline erodes operating scale and reflects weak commercial inflows. For a clinical-stage biotech, this magnifies dependency on milestone/collaboration cash and heightens execution risk: sustained low revenue undermines internal funding capacity and strategic optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Reported gross margin near 96% implies strong unit economics for Atara’s biologics if commercialized. Durable high margins support long-term profitability per therapy sold and improve the potential return on successful R&D investments, partially offsetting development-stage cost intensity.
Read all positive factors
Atara Biotherapeutics (ATRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$86.32M
Dividend YieldN/A
Average Volume (3M)342.43K
Price to Earnings (P/E)―
Beta (1Y)0.66
Revenue Growth-88.41%
EPS Growth76.14%
CountryUS
Employees153
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.66
Shares Outstanding9,010,172
10 Day Avg. Volume70,555
30 Day Avg. Volume342,427
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-5.89
Price to Sales (P/S)1.88
P/FCF Ratio-4.45
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue3.56
Enterprise Value/Gross Profit3.70
Enterprise Value/Ebitda-14.86
Forecast
1Y Price Target
$15.50Price Target Upside-1.84% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.69
Revenue Forecast (FY)$16.27M
Atara Biotherapeutics Business Overview & Revenue Model
Company Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 c...
How the Company Makes Money
Atara Biotherapeutics has historically generated revenue primarily from collaboration and licensing arrangements rather than from large-scale product sales, reflecting its clinical-stage profile. Key revenue streams typically include (1) collabora...
Atara Biotherapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
14
Very Negative
Cash Flow
9
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.14M | 120.77M | 128.94M | 8.57M | 63.57M | 20.34M |
| Gross Profit | 22.24M | 99.56M | 107.93M | -313.00K | 63.57M | -261.66M |
| EBITDA | -5.54M | 38.63M | -75.75M | -266.00M | -222.26M | -331.12M |
| Net Income | -9.47M | 32.69M | -85.40M | -276.13M | -228.30M | -340.14M |
Balance Sheet | ||||||
| Total Assets | 20.00M | 20.23M | 109.10M | 165.50M | 376.42M | 468.13M |
| Cash, Cash Equivalents and Short-Term Investments | 8.36M | 8.48M | 42.50M | 51.73M | 242.82M | 371.07M |
| Total Debt | 9.08M | 52.80M | 43.83M | 57.87M | 71.70M | 28.27M |
| Total Liabilities | 57.31M | 58.74M | 206.38M | 264.74M | 249.78M | 188.51M |
| Stockholders Equity | -37.31M | -38.50M | -97.28M | -99.23M | 126.64M | 279.61M |
Cash Flow | ||||||
| Free Cash Flow | -25.88M | -50.94M | -68.96M | -194.20M | -274.62M | -231.10M |
| Operating Cash Flow | -25.88M | -50.94M | -68.72M | -192.98M | -270.43M | -220.52M |
| Investing Cash Flow | 949.00K | 18.15M | 8.62M | 123.87M | 202.96M | 22.26M |
| Financing Cash Flow | 19.30M | 16.10M | 59.28M | 2.01M | 53.08M | 103.94M |
Atara Biotherapeutics Technical Analysis
Neutral
15.79
Price Trends
5.04
Positive
8.66
Negative
10.58
Negative
Market Momentum
-0.07
Negative
52.41
Neutral
80.32
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATRA, the sentiment is Neutral. The current price of 15.79 is above the 20-day moving average (MA) of 4.90, above the 50-day MA of 5.04, and above the 200-day MA of 10.58, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 52.41 is Neutral, neither overbought nor oversold. The STOCH value of 80.32 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ATRA.
Atara Biotherapeutics Risk Analysis
Atara Biotherapeutics disclosed 64 risk factors in its most recent earnings report. Atara Biotherapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Atara Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $288.30M | -1.16 | -53.61% | ― | -100.00% | 44.78% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $86.32M | -4.02 | -79.12% | ― | -88.41% | 76.14% | |
50 Neutral | $270.14M | -1.25 | -147.80% | ― | 1.97% | -25.03% | |
47 Neutral | $65.35M | -1.14 | -91.94% | ― | 106.65% | 12.20% | |
45 Neutral | $326.83M | -0.63 | 309.79% | ― | -35.61% | -68.92% |
* Healthcare Sector Average
ATRA
Atara Biotherapeutics
9.58
2.85
42.35%
MGNX
MacroGenics
4.25
2.66
167.30%
ZNTL
Zentalis Pharmaceuticals
4.05
2.80
224.00%
SRZN
Surrozen
28.15
20.12
250.56%
TCRX
TScan Therapeutics
1.00
-0.24
-19.35%
Atara Biotherapeutics Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Atara Biotherapeutics Gains Clearer FDA Path for Tab-cel
Positive
May 7, 2026
On May 7, 2026, Atara Biotherapeutics announced that partner Pierre Fabre Pharmaceuticals had a constructive Type A meeting with the U.S. Food and Drug Administration regarding the Complete Response Letter issued on January 9, 2026 for the Biologi...
Delistings and Listing ChangesRegulatory Filings and Compliance
Atara Biotherapeutics Receives Nasdaq Non-Compliance Delisting Notice
Negative
May 1, 2026
On April 30, 2026, Atara Biotherapeutics received notice from Nasdaq that it no longer meets the $50 million minimum market value of listed securities required for continued listing on the Nasdaq Global Select Market. The company has until October...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Atara Plans FDA Type A Meeting on EBVALLO
Neutral
Mar 12, 2026
On March 12, 2026, Atara Biotherapeutics announced that it has scheduled a Type A meeting with the U.S. Food and Drug Administration to discuss the Complete Response Letter issued on January 9, 2026, for the Biologics License Application of its pr...
Product-Related AnnouncementsRegulatory Filings and Compliance
Atara, Pierre Fabre seek FDA meeting on EBVALLO
Negative
Mar 3, 2026
On March 3, 2026, Atara Biotherapeutics reported that its partner Pierre Fabre Pharmaceuticals has requested a Type A meeting with the U.S. Food and Drug Administration to address issues raised in the Complete Response Letter issued on January 9, ...
Business Operations and StrategyPrivate Placements and Financing
Atara Biotherapeutics Extends Royalty Milestone, Issues Warrant
Positive
Feb 23, 2026
On February 20, 2026, Atara Biotherapeutics amended its existing Purchase and Sale Agreement with a fund managed by HealthCare Royalty, pushing back a one-time $9.0 million milestone payment tied to its Pierre Fabre commercialization deal from Jun...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.